Lyra Therapeutics, Inc.
NASDAQ: LYRA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carmichael S. Roberts Jr.
- Employees
- 30
- Headquarters
- Watertown, United States
- IPO year
- 2020
- Market cap
- $781.1K
- Website
- https://lyratherapeutics.com
Loading LYRA…
Loading profile data…Frequently asked questions about LYRA
What does Lyra Therapeutics, Inc. (LYRA) do?
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, e...
Where does LYRA trade?
Lyra Therapeutics, Inc. (LYRA) trades on the NASDAQ Global Market.
What sector is LYRA in?
Lyra Therapeutics, Inc. (LYRA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lyra Therapeutics, Inc.?
Carmichael S. Roberts Jr. is the chief executive officer of Lyra Therapeutics, Inc. (LYRA).
Where is Lyra Therapeutics, Inc. headquartered?
Lyra Therapeutics, Inc. is headquartered in United States.
Does LYRA pay a dividend?
Lyra Therapeutics, Inc. (LYRA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LYRA go public?
Lyra Therapeutics, Inc. (LYRA) completed its initial public offering in 2020.